Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):36-39. doi: 10.22608/APO.2017466. Epub 2017 Dec 27.

Abstract

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy.

Keywords: bevacizumab; diabetic macular edema; intravitreal injections; proliferative diabetic retinopathy; tractional retinal detachment.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / administration & dosage
  • Bevacizumab / therapeutic use*
  • Chemotherapy, Adjuvant
  • Diabetic Retinopathy / drug therapy*
  • Humans
  • Intravitreal Injections
  • Macular Edema / drug therapy*
  • Preoperative Care

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab